Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A phase 3 trial found that adding the HDAC inhibitor HBI-8000 to nivolumab significantly improved progression-free survival in patients with unresectable advanced melanoma. After 37 months of follow-up, median PFS jumped from 7.36 to 11.66 months — and nearly tripled in patients with normal LDH levels. Researchers say the combo could become a new standard-of-care option.
A new drug combo is turning heads in advanced melanoma treatment. Results from the phase 3 HBI-8000-303 trial, presented at ESMO 2026, show that pairing the novel HDAC inhibitor HBI-8000 with the immunotherapy nivolumab significantly outperformed nivolumab plus placebo in patients with unresectable stage III or IV non-uveal melanoma. The study enrolled 404 patients who had not previously received immune checkpoint inhibitors.
After a median follow-up of 37 months, the HBI-8000 combination extended median progression-free survival (PFS) and boosted response rates — with researchers noting the benefit was consistent across most patient subgroups. Study presenter Dr. Nikhil Khushalani called the regimen a potential "standard-of-care option," highlighting its oral dosing convenience and manageable toxicity profile.
By the Numbers:
Why it matters: Advanced melanoma remains difficult to treat, and this combination offers a meaningful PFS improvement — especially for patients with normal LDH levels — while maintaining a largely reversible side effect profile. If approved more broadly, HBI-8000 could expand the immunotherapy toolkit for oncologists managing this aggressive cancer.
